SGLT2 Inhibitors: Unreal Primary Prevention? | Latest News RSS feed

SGLT2 Inhibitors: Unreal Primary Prevention? - Latest News

Eli Lilly Is An Attractive Buy For 2018

Belonging to the SGLT2 class of drugs, Jardiance has already benefitted ... Then we have Verzenio, a metastatic breast cancer drug which is third-to-market CDK inhibitor in the U.S., after Ibrance and ... read more

New Method to Deliver Glucose to Cancer Cells Could Prove Key to Defeating Deadly Cancers

Cancer cells require high amounts of glucose to grow and survive, and long-standing research has established passive glucose transporters (or GLUTS) as the primary delivery ... it provides strong evid... read more

Study reveals sotagliflozin in conjunction with insulin reduces average blood glucose levels

the ADA's peer-reviewed research journal dedicated to diabetes treatment and prevention. Sotagliflozin is an investigational dual inhibitor of sodium glucose transport proteins 1 and 2 (SGLT1 and SGLT... read more

Looking for another news?

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

"The AWARD-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals." ... read more

Boehringer Ingelheim, Lilly ink academic collaboration with University of Oxford to investigate effects of empagliflozin in people with CKD

The primary outcome of the study is to assess the effect of ... the largest clinical development programme of an SGLT2 inhibitor. “We are delighted to partner with such a prestigious academic institut... read more

Repatha's Next Challenge Is Expectations

Both will have much to prove, as payers are eager to see whether a profound reduction of LDL can translate into prevention of cardiovascular complications ... The anti-diabetic SGLT-2 drugs have earne... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us